Shire Acquires Lumena Pharmaceuticals - - BioPharm International

ADVERTISEMENT

Shire Acquires Lumena Pharmaceuticals



Shire has acquired Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for $260 million.

According to the company, the acquisition of Lumena will expand Shire’s rare disease pipeline and provide future opportunities for Shire’s gastrointestinal business. Lumena Pharmaceuticals brings to Shire two new oral therapeutic compounds for hepatic diseases; LUM001, in Phase 2 with four potential orphan indications and LUM002, ready to enter Phase 2 later in 2014.

LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, which is primarily responsible for recycling bile acids from the intestine to the liver.

Shire does not expect the acquisition of Lumena to result in a change to its previously stated earnings guidance for 2014.

Source: Shire

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here